Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Bavarian Nordic Announces Presentation of Phase 1 Data for its RSV Vaccine at International RSV Symposium | ||
By: Nasdaq / GlobeNewswire - 29 Sep 2016 | Back to overview list |
|
COPENHAGEN, Denmark, September 29, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the presentation of data from a Phase 1 study of its novel, broad spectrum RSV (respiratory syncytial virus) vaccine candidate, MVA-BN RSV ® . The Phase 1 was a dose ranging study which enrolled 63 volunteers, including the elderly. The presentation, entitled " A randomized, single-blind, placebo-controlled Phase 1 trial to evaluate the safety, tolerability, and immunogenicity of the recombinant MVA-BN RSV ® vaccine in healthy adult subjects " will take place today at the 10th International Respiratory Syncytial Virus Symposium in Patagonia, Argentina. As was previously reported, MVA-BN RSV was well tolerated, with no unexpected or serious adverse reactions. A significant boost in antibodies and T cells against RSV was measured in all groups following vaccination including antibodies against both RSV subtypes, A&B. Also of note was the production of IgA, a specialized antibody that is transported from the blood to the mucosal surfaces (e.g. nose, throat, lungs) potentially allowing for protection against RSV at the point of infection/inflammation. Based on these data, a Phase 2 study in 400 subjects will begin this fall. A link to the abstract can be found on the conference website, www.rsv16.org , and a copy of the slide presentation will be available on the company's website, www.bavarian-nordic.com under Investors > Events & Presentations.
About RSV
About Bavarian Nordic
Forward-looking statements
Contacts
Seth Lewis
Press Release
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Bavarian Nordic A/S via GlobeNewswire
HUG#2045513
|
||
|
||
Copyright 2016 Nasdaq / GlobeNewswire | Back to overview list |